Tactical Therapeutics Competitors and Similar CompaniesClear all

Tactical Therapeutics's competitors and similar companies include Curtana Pharmaceuticals, Biocon, Shanghai Junshi Biosciences and Kyowa Kirin.
Tactical Therapeutics
Tactical Therapeutics
Tactical Therapeutics (TTI) is a clinical-stage company that develops a therapeutic for the orphan indication glioblastoma (GBM) and other refractory targets.
Curtana Pharmaceuticals
Curtana Pharmaceuticals
Curtana Pharmaceuticals is a company specializing in therapies for brain cancer.
Biocon
Biocon
Biocon is a company that develops and manufactures biopharmaceutical products.
Shanghai Junshi Biosciences
Shanghai Junshi Biosciences
Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.
Kyowa Kirin
Kyowa Kirin
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
Founding Date
Founding Date
N/A
Founding Date
2013
Founding Date
1978
Founding Date
2012
Founding Date
2008
Type
Type
Private
Type
Private
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
New York, US HQ
Locations
Austin, US HQ
Locations
Bengaluru, IN HQ
Bengaluru, IN
Nanakramguda, IN
Dublin, IE
Kuala Lumpur, MY
Puchong, MY
Delémont, CH
see more
Locations
Shanghai, CN HQ
Locations
Tokyo, JP HQ
Sydney, AU
Shanghai, CN
Prague, CZ
Tampere, FI
Düsseldorf, DE
Hong Kong, HK
see more
Employees
Employees
N/A
Employees
7
Employees
16,5612% increase
Employees
2,578
Employees
5,669

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
₹167.8b (FY, 2026)
Revenue (est.)
¥2.4b (FY, 2025)
Revenue (est.)
¥496.8b (FY, 2025)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
₹56.9b (FY, 2026)
Cost of goods
¥466.5m (FY, 2025)
Cost of goods
¥114.3b (FY, 2025)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
₹115.8b (FY, 2026)
Gross profit
¥2b (FY, 2025)
Gross profit
¥383.4b (FY, 2025)
Net income
Net income
N/A
Net income
N/A
Net income
₹3.7b (FY, 2026)
Net income
(¥1b) (FY, 2025)
Net income
¥67b (FY, 2025)
For sources of this data, please see the company profile

View Company Profiles

Curtana Pharmaceuticals
HQ
Austin, US
Employees
7

Curtana Pharmaceuticals is a company specializing in therapies for brain cancer.

View company
Biocon
HQ
Bengaluru, IN
Employees
16,561↑ 2% increase

Biocon is a company that develops and manufactures biopharmaceutical products.

View company
Shanghai Junshi Biosciences
HQ
Shanghai, CN
Employees
2,578

Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.

View company
Kyowa Kirin
HQ
Tokyo, JP
Employees
5,669

Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.

View company